In vitro activity of daptomycin & linezolid against methicillin resistant staphylococcus aureus & vancomycin resistant enterococci isolated from hospitalized cases in central India

Indian Journal of Medical Research

Volumn 137, Issue 1, 2013, Pages 191-196

  Chitnis, Sheetal ^a   Katara, Gunjan ^a   Hemvani, Nanda ^a   Pareek, Siddika ^a   Chitnis, Dhananjay Sadashiv ^a  

^a CHOITHRAM HOSPITAL AND RESEARCH CENTRE   (India)

Author keywords

Daptomycin; Linezolid; Methicillin resistant staphylococcus aureus; Minimum inhibitory concentration; Vancomycin resistant enterococci

Indexed keywords

AMIKACIN; AMPICILLIN; CEFALORIDINE; CEFEPIME; CEFOPERAZONE; CEFOTAXIME; CEFOXITIN; CEFTRIAXONE; CHLORAMPHENICOL; CIPROFLOXACIN; CLINDAMYCIN; COTRIMOXAZOLE; DAPTOMYCIN; ERYTHROMYCIN; GENTAMICIN; LINEZOLID; NETILMICIN; OXACILLIN; SULPERAZON; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATION; DISK DIFFUSION; ENTEROCOCCUS FAECIUM; EPSILOMETER TEST; GENOTYPE; HOSPITAL PATIENT; HUMAN; IN VITRO STUDY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MINIMUM INHIBITORY CONCENTRATION; MULTIPLEX POLYMERASE CHAIN REACTION; TEST STRIP; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; DAPTOMYCIN; ENTEROCOCCUS; HUMANS; INDIA; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; OXAZOLIDINONES; TEICOPLANIN; VANCOMYCIN RESISTANCE;

EID: 84874749523     PISSN: 09715916     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Dinubile MJ, Lipsky BA. Complicated infections of skin and skin structures: when the infection is more than skin deep. J Antimicrob 2004; 53 (Suppl S2): ii37-50.
2. Petti CA, Fowler Jr VG. Staphylococcus aureus bacteremia and endocarditis. Cardiol Clin 2003; 21: 219-33.
3. Philip IH, Susan JK. Datpomycin a review of its use in the management of complicated skin and soft tissue infections and Staphylococcus aureus bacteraemia. Drug 2007; 67: 1483-512.
4. Swaney SM, Aoki H, Ganoza MC, Shinbarger DL. The oxazolidinone linezolid inhibits intiation of protein synthesis in bacteria. Antimicrob Agents Chemother 1998; 42: 3251-5.
5. Diederen BMW, Duijn IV, Willemse P, Klutymans JW. In vitro activity of daptomycin against methicillin resistant Staphylococcus aureus including heterogeneously glycopeptide resistant strains. Antimicrob Agents Chemother 2006; 50: 3189-91.
6. Biedenach DJ, Bell JM, Sader HS, Fritsche TR, Jones RN, Turnidge JD. Antimicrobial susceptibility of gram positive bacterial isolates from the Asia Pacific region and an in vitro evaluation of the bactericidal activity of daptomycin, vancomycin and teicoplanin: a SENTRY program report (2003-2004). Int J Antimicrob Agents 2007; 30: 143-9.
7. Rybak MJ, Hersberger E, Moldovan T, Gruz RG. In vitro activities of daptomycin, vancomycin, linezolid and quinupristin-dalfopristin against staphylococci and enterococci including vancomycin intermediate and resistant strains. Antimicrob Agents Chemother 2000; 44: 1062-6.
8. Sader HS, Wallers AA, Fritsche TR, Jines RN. Daptomycin antimicrobial activity tested against methicillin resistant staphylococci and vancomycin resistant enterococci isolated in European medical centres (2005). BMC Infect Dis 2007; 18: 29.
9. Sader HS, Streit JM, Fritsche TR, Jones RN. Antimicrobial susceptibility of gram positive bacteria isolated from European medical centres: results of the daptomycin surveillance programme (2002-2004). Clin Microbiol Infect 2006; 12: 844-52.
10. Jorgen B, Merckoll P, Melby KK. Susceptibility to daptomycin, quinupristin-dalfopristin and linezolid and some other antibiotics in clinical isolates of methicillin resistant and methicillin sensitive S. aureus from the Oslo area. Scand J Infect Dis 2007; 39: 1059-62.
11. Loza E, Morosini MI, Pascual A, Tubau F, Alcala J, Linares J, et al. Comparative in vitro activity of daptomycin against gram positive microorganisms: SENTRY surveillance program, Spain (2002-2006). Enferm Infect Microbiol Clin 2008; 26: 489-94.
12. Zhanel GG, Décorby M, Nichol KA, Wierzboski A, Baudry PJ, Karlowsky JA, et al. Canadian Antimicrobial Resistance Alliance (2008). Antimicrobial susceptibility of 3931 organisms isolated from intensive care units in Canada:Canadian National intensive care unit study, 2005-2006. Diagn Microbiol Infect 2008; 62: 67-80.
13. Dhawan B, Gadepalli R, Kapil A. In vitro activity of daptomycin against Staphylococcus aureus and vancomycin resistant enterococcus faecium isolates associated with skin and soft tissue infections: first results from India. Diagn Microbiol Infect Dis 2009; 65: 196-8.
14. Mathai D, Biedenbach DJ, Jones RN, Bell JM, Turnidge J Sader HS; India Daptomycin Study group. Activity of daptomycin against Gram positive bacterial isolates from Indian medical centre (2006-2007). Int J Antimicrob Agents 2009; 34: 497-9.
15. Namita DS, Shetty A, Mehta A, Rodrigues C. Antimicrobial susceptibility profiles of methicillin susceptible and resistant Staphylococcus aureus: focus on daptomycin minimum inhibitory concentration at a tertiary care centre in Mumbai, India. Int J Antimicrob Agents 2010; 36: 267-70.
16. Baird D. Staphylococcus: cluster-forming Gram positive cocci. In: Collee AG, Fraser BP, Marmion JG, Simmons A, editors. Mackie and McCartney practical medical microbiology, 14th ed. New York: Churchill Livingstone; 1996. p. 245-61.
17. Facklam RR, Collins MD. Identification of Enterococcus species isolated from human infections by a conventional test scheme. J Clin Microbiol 1989; 27: 731-4.
18. Bauer AW, Kirby WM, Sherris JC, Truck M. Antibiotic susceptibility by standardized single disc method. Am J Clin Pathol 1966; 45: 493-6.
19. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 21st Informational Supplement. (M100-S21). Wayne, Pa, USA: Clinical and Laboratory Standards Institute; 2010.
20. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing. 19th Informational Supplement. (M100-S19). Wayne, Pa, USA: Clinical and Laboratory Standards Institute; 2009.
21. Dutkan MS, Evens SC. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. Clin Microbiol Infect 1995; 33: 24-7.
22. Verma S, Joshi S, Chitnis V, Hemwani N, Chitnis D. Growing problem of methicillin resistant staphylococci - Indian scenario. Indian J Med Sci 2000; 54: 535-40.
23. Rao GG. Should clindamycin be used in the treatment of patients with infections caused by erythromycin-resistant staphylococci? J Antimicrob Chemother 2000; 45: 709-17.
24. Sader HS, Jones RN, Rossi KL, Rybak MJ. Occurrence of vancomycin tolerant and heterogenous vancomycin intermediate strains (hiVISA) among S. aureus causing blood stream infection in nine USA hospital. J Antimicrob Chemother 2009; 64: 1024-8.
25. Rybak MJ, Lomaestro BM, Rotschafer JC, Moellering RC, Craig WA, Billeter M, et al. Vancomycin therapeutic guideline. A summary of consensus recommendation from infectious disease society of America, the American society of health system pharmacists and the society of infectious diseases pharmacists. Clin Infect Dis 2009; 49: 325-7.
26. Silverman JA, Mortin LI, Vanpraagh AD, Li T, Alder J. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191: 2149-52.
27. Perry CM, Jaris B. Linezolid: a review of its use in the management of serious gram positive infections. Drugs 2001; 61: 525-51.
28. Gruchalla RS, Pirmohamed M. Antibiotic allergy. N Engl J Med 2006; 354: 601-9.
29. Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI; Daptomycin 98-01 and 99-01 Investigators. The safety and efficacy of daptomycin for the treatment of complicated skin and skin structure infections. Clin Infect Dis 2004; 38: 1673-81.